周一，生物技术公司Replimune 盘初飙升115%，此前宣布美国食品药品监督管理局（FDA）接受了其皮肤癌药物重新提交的审批申请。
周一，生物技术公司Replimune 盘初飙升115%，此前宣布美国食品药品监督管理局（FDA）接受了其皮肤癌药物重新提交的审批申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
